Core Viewpoint - The controversy surrounding Aikang Guobin involves allegations of "fake health check-ups" after a lawyer, Zhang Xiaoling, was diagnosed with cancer despite years of normal test results from the company [1][2]. Group 1: Allegations and Responses - Zhang Xiaoling claims that Aikang Guobin's health checks failed to detect her cancer risk over a decade, leading to a late-stage diagnosis [1][2]. - Aikang Guobin has conducted internal and external evaluations, asserting that there were no misdiagnoses or false checks, and has initiated legal action against Zhang for defamation [2][6]. - The company emphasizes that health checks are not equivalent to medical diagnoses and are intended to identify potential health issues for further investigation by specialists [3]. Group 2: Medical Insights and Procedures - Aikang Guobin's medical professionals clarified that the 2023 ultrasound report indicated potential issues that warranted further examination, contradicting Zhang's claims [3][5]. - The company highlighted that cancer markers like carcinoembryonic antigen (CEA) are not reliable for early detection of kidney cancer, as imaging techniques are the primary diagnostic tools [5]. - Aikang Guobin maintains that it follows industry standards regarding the retention of blood samples, which typically last only 1-7 days, making it impossible to keep samples from the past decade [4]. Group 3: Impact on the Industry - The allegations have raised concerns about public trust in private health check-up centers and the broader healthcare industry in China, affecting the reputation of Aikang Guobin and its employees [6]. - The company asserts that the claims have harmed its reputation and the trust of its approximately 8 million annual clients [6].

Core Viewpoint - Aikang Guobin has initiated legal proceedings regarding a dispute over cancer screening with a client, Ms. Zhang, and the court has officially accepted the case [1] Group 1: Company Actions - Aikang Group's Senior Vice President, Zhou Xiaojiang, announced the lawsuit against Ms. Zhang during a press conference [1] - The company emphasizes the importance of seeking specialized medical advice if abnormalities are detected during health check-ups [1] Group 2: Industry Insights - Aikang Group's founder and CEO, Zhang Ligang, stated that cancer development is a gradual process and early detection may be limited by technological constraints [1] - The company highlights that health check-ups cannot replace specialized medical diagnosis and further examinations are necessary if any issues are found [1]

Meeting Overview - The shareholders' meeting of Meinian Health Industry Holdings Co., Ltd. was held on July 28, 2025, with a total of 921 participants representing 1,277,900,984 shares, accounting for 32.6474% of the total shares [1] - The online voting took place from 9:15 AM to 3:00 PM on the same day, with 916 shareholders participating, representing 749,647,534 shares, or 19.1517% of the total shares [2] Voting Results - The meeting adopted resolutions with a significant majority, where 1,272,894,440 shares voted in favor, representing 99.6082% of the valid votes [2] - A total of 4,509,144 shares opposed the resolutions, accounting for 0.3529%, while 497,400 shares were abstained [2] Minority Shareholder Participation - Among the minority investors, 282,237,144 shares voted in favor, which is 98.2570% of the valid votes from minority shareholders [3] - The opposition from minority shareholders was 4,509,144 shares, representing 1.5698% [3] Related Party Transactions - The resolutions involved related party transactions, with specific shareholders, including Yu Rong and several asset management companies, abstaining from voting [3][4] - The voting results from non-related shareholders showed 738,065,801 shares in favor, which is 98.4550% of the valid votes [4] Detailed Voting Breakdown - The detailed voting results indicated that among non-related minority shareholders, 275,661,955 shares voted in favor, representing 95.9680% [4] - The opposition from this group was 11,086,633 shares, accounting for 3.8597% [4] Conclusion of Resolutions - All resolutions requiring a two-thirds majority from non-related shareholders were successfully passed according to the company's articles of association [4][5] - The resolutions included significant related party transactions, with the relevant shareholders abstaining from the voting process [5][6]

Core Viewpoint - The article highlights a charitable health screening event organized by Ciming Health Checkup Group for retired soldiers, emphasizing the importance of honoring and caring for veterans as a social responsibility and a way to express gratitude for their service [1][4][9]. Group 1: Event Overview - The "Welcoming August 1st, Warming Veterans" charity event took place on July 22, where 29 retired soldiers received health checkups, aiming to enhance their sense of honor, belonging, and happiness [1][4]. - Ciming Health Checkup Group, in collaboration with the Dahongmen Street Office, meticulously planned the event to ensure a memorable experience for the veterans [4][6]. Group 2: Health Services Provided - The health checkup included a comprehensive range of services tailored to the veterans' age and health needs, covering various medical specialties and tests such as internal medicine, external medicine, and cancer screenings [4][12]. - Medical staff provided personalized health guidance based on each veteran's health status, lifestyle, and medical history, ensuring a thorough and caring approach [4][12]. Group 3: Community and Corporate Responsibility - The event was praised by local officials, highlighting the importance of community support for veterans and the ongoing efforts to improve the service and support system for retired military personnel [6][8]. - Ciming Health Checkup Group has previously donated 1.68 million yuan for health checkups for low-income veterans, demonstrating a commitment to social responsibility and the well-being of retired soldiers [8][9]. Group 4: Future Initiatives - Ciming Health Checkup Group plans to continue expanding its charitable services, aiming to provide high-quality health services to a broader audience while fostering a culture of respect and care for veterans [12].

Core Viewpoint - The controversy surrounding Aikang Guobin's health check services has emerged after a lawyer, Zhang Xiaoling, claimed that her ten years of health check reports showed no cancer risk, yet she was later diagnosed with late-stage kidney cancer. This raises questions about the reliability of routine health checks and cancer screening methods [2][3][8]. Group 1: Company Response - Aikang Guobin has conducted internal reviews and external expert evaluations, asserting that they bear no responsibility for the alleged oversight in Zhang's health checks and are open to third-party assessments [11][18]. - The company stated that Zhang's 2023 report indicated a "right kidney calcification focus" and a "possible left kidney hamartoma," contradicting her claims of no abnormalities [8][11]. - Aikang emphasized that cancer detection is a complex process influenced by various factors, including the timing of tests and the methods used, and that some cancers may not be detectable at certain stages [19][20]. Group 2: Industry Insights - The cancer screening industry is evolving, with a projected market size of $20.82 billion in 2022, expected to reach $28.93 billion in 2023, highlighting the growing demand for effective early detection methods [26][27]. - Current cancer screening technologies primarily include X-rays, CT scans, MRI scans, and ultrasound, while advanced techniques like liquid biopsies and AI-assisted imaging are being developed [27]. - Experts recommend that individuals over 40 should undergo annual ultrasound checks for urinary system cancers, as conventional blood tests may not reliably indicate kidney cancer risk [20][21].

Core Viewpoint - The controversy surrounding Aikang Guobin's health check services has sparked public concern, particularly regarding the accuracy of cancer risk detection over a decade-long period [2][4]. Group 1: Incident Overview - A lawyer, Zhang Xiaoling, underwent health checks at Aikang Guobin for 10 consecutive years without any cancer warnings, only to be diagnosed with late-stage kidney cancer in 2024 [4]. - Zhang claims that Aikang Guobin failed to inform her of potential cancer risks despite a 2023 report indicating a "calcium spot" on her right kidney [4]. - After switching to a different health check provider, Zhang was diagnosed with kidney cancer, which had already metastasized to her bones by early 2025 [4]. Group 2: Company Response - Aikang Group stated that cancer detection depends on various factors, including the timing of the check, methods used, and the expertise of the medical staff [5]. - The company emphasized that their reports accurately reflect the results of the checks conducted at the time and that they would seek third-party verification if any responsibility is claimed [5]. - Aikang Group noted that Zhang's 2023 report did indicate potential issues, and the growth of her cyst from 2023 to 2024 fell within the range typical for cancer progression [5]. Group 3: Industry Context - Aikang Guobin has faced multiple complaints regarding inaccurate health reports and perceived negligence in their services, with over 1,300 complaints recorded on the Black Cat Complaint platform [6]. - The company was founded in 2004 and went public on NASDAQ in 2014, later privatizing in 2019 [9].

Core Viewpoint - The article discusses a controversy surrounding Aikang Group regarding the alleged failure to detect cancer risks in a client, leading to a late-stage kidney cancer diagnosis, raising questions about the effectiveness and reliability of their health check services [1][2]. Group 1: Company Response - Aikang Group issued a second statement confirming that their medical team reviewed the client's health records and found no diagnostic errors in the kidney examinations, asserting that their reports were accurate and consistent with ultrasound results [1][4]. - The company expressed willingness to accept third-party evaluations and take responsibility if found at fault, emphasizing their commitment to transparency and accountability [2][4]. Group 2: Client's Allegations - The client, lawyer Zhang Xiaoling, criticized Aikang's response as evasive, claiming it relied on "medical uncertainty" while neglecting systemic failures and data management issues [2][3]. - Zhang highlighted that Aikang had not provided requested documentation related to her health checks, including blood test data and the validity of specific cancer detection technologies [3][4]. Group 3: Importance of Professional Interpretation - Zhang argued that the value of health check services lies in the professional interpretation of results, which Aikang failed to provide, as clients often lack the medical knowledge to understand their reports [4]. - The company has a network of 170 health check centers across 54 cities in China, serving approximately 10 million individuals annually, indicating a significant scale of operations [4].

Core Viewpoint - The article discusses a complaint against iKang Guobin regarding a failure to detect cancer during routine health check-ups, highlighting issues of accountability and the adequacy of their testing methods [1][2][6]. Group 1: Complaint Details - The complainant, Zhang Xiaoling, argues that iKang Guobin's response shifts all responsibility to the user, claiming that the company did not provide adequate information on the timing and methods of tests [2][3]. - Zhang Xiaoling expresses frustration over the lack of clarity regarding the detection capabilities of iKang Guobin, questioning why users should pay for health checks if potential issues are not identified [2][3]. - iKang Guobin stated that the ability to detect cancer depends on various factors, including the timing of the check-up and the methods used, but Zhang disagrees with this explanation [1][2]. Group 2: Company Response and History - iKang Guobin has publicly stated that they have contacted Zhang Xiaoling but have not taken action on her request for testing samples and imaging [4]. - The company has faced multiple complaints in recent years regarding inaccurate health reports, misdiagnoses, and negligence in testing procedures, with over 1,306 complaints recorded on a third-party platform [6]. - The ongoing controversy surrounding the alleged misdiagnosis and negligence continues to attract public attention, with further developments expected [8].

Group 1 - The core issue revolves around a woman who underwent annual health check-ups for 10 years without any cancer detection, only to be diagnosed with late-stage cancer later, raising concerns about the effectiveness of the health screening process [2][3] - Aikang Group stated that cancer detection depends on various factors including the timing of the tests, methods used, and the expertise of the medical professionals involved, indicating that some cancers may not be detectable at certain times [2][3] - Aikang Group plans to collaborate with a third-party authority to analyze the situation and validate the accuracy of the health check results provided to the individual [2][3] Group 2 - The woman, Zhang Xiaoling, reported that her cancer marker tests had consistently shown normal results over the years, but a later examination revealed abnormalities leading to a diagnosis of renal cell carcinoma [3] - The incident has prompted legal action from Zhang against Aikang Group, alleging potential oversight or misdiagnosis in her health assessments [3]

Core Viewpoint - The article highlights concerns regarding the accuracy of health check-ups conducted by Aikang Guobin, particularly in detecting cancer, as multiple users report misdiagnoses and missed diagnoses leading to severe health consequences [1][3][12]. Group 1: User Experiences - A woman who had regular check-ups for 10 years at Aikang Guobin was later diagnosed with kidney cancer, raising questions about the reliability of the tests [1][4]. - Users reported instances of misdiagnosis, such as one individual being told their kidneys were normal only to be diagnosed with kidney cancer shortly after [1][4]. - Another case involved a man whose oral examination indicated only minor issues, yet he was later diagnosed with tongue cancer, suggesting a failure in the screening process [6][8]. Group 2: Company Response and Accountability - Aikang Guobin stated that the detection of cancer depends on various factors, including the timing of the tests and the methods used, and they would take responsibility if found at fault [1][6]. - The company has faced criticism for its lack of communication with affected families and for not addressing complaints adequately, leading to perceptions of evasion of responsibility [6][9]. - Users have expressed frustration over the complicated and costly process required to seek accountability from Aikang Guobin, which they feel is designed to deter claims [6][9]. Group 3: Testing Methods and Efficacy - The article discusses the "carcinoembryonic antigen (CEA) test," which is used as a tumor marker but has limitations in specificity and sensitivity, leading to potential false negatives and positives [10][11]. - Experts generally do not recommend the CEA test as a routine screening method for healthy individuals due to its low specificity [11][12]. - Aikang Guobin claims to serve around 10 million individuals annually, but the rising complaints about inaccurate results could jeopardize their reputation and user trust [13].